Elevation of Endocannabinoids via Inhibition of their Catabolic Enzymes Attenuates the Precipitated Opioid Withdrawal Syndrome

被引：0
|
作者：
Ramesh, Divya [1 ]
Long, Jonathan Z. [2 ,3 ]
Ahn, Kay [4 ]
Cravatt, Benjamin F. [2 ,3 ]
Lichtman, Aron H. [1 ]
机构：
[1] Virginia Commonwealth Univ, Richmond, VA USA
[2] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA
[4] Pfizer Global Reasearch & Dev, Groton, CT USA
来源：
FASEB JOURNAL | 2010年 / 24卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：1
相关论文
共 45 条
  • [21] SU-6656, a Selective Src Kinase Inhibitor, Attenuates Mecamylamine-Precipitated Nicotine Withdrawal Syndrome in Mice
    Rehni, Ashish K.
    Singh, Thakur Gurjeet
    Arora, Sandeep
    NICOTINE & TOBACCO RESEARCH, 2012, 14 (04) : 407 - 414
  • [22] In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator
    Singh, Prabhat
    Sharma, Bhupesh
    Gupta, Surbhi
    Sharma, B. M.
    PSYCHOPHARMACOLOGY, 2015, 232 (02) : 465 - 475
  • [23] In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator
    Prabhat Singh
    Bhupesh Sharma
    Surbhi Gupta
    B. M. Sharma
    Psychopharmacology, 2015, 232 : 465 - 475
  • [24] Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists
    Popik, P
    Mamczarz, J
    Fraczek, M
    Widla, M
    Hesselink, M
    Danysz, W
    NEUROPHARMACOLOGY, 1998, 37 (08) : 1033 - 1042
  • [25] Nalmefene attenuates malignant potential in colorectal cancer cell via inhibition of opioid receptor
    Wu, Qichao
    Chen, Xiangyuan
    Wang, Jiaqiang
    Sun, Pengfei
    Weng, Meilin
    Chen, Wankun
    Sun, Zhirong
    Zhu, Minmin
    Miao, Changhong
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2018, 50 (02) : 156 - 163
  • [26] Pharmacological modulation of leukotriene D4 attenuates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome
    Rehni, Ashish K.
    Singh, Inderbir
    Singh, Nirmal
    Bansal, Nitin
    Bansal, Seema
    Kumar, Manoj
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 598 (1-3) : 51 - 56
  • [27] A case of life-threatening opioid withdrawal syndrome precipitated by buprenorphine abuse in 61 year-old methadone dependent patient
    Wiegand, Timothy J.
    CLINICAL TOXICOLOGY, 2013, 51 (04) : 349 - 349
  • [28] Withdrawal syndrome is not precipitated when butorphanol is added to opiate or opioid therapy - A comment on intranasal butorphanol-induced apraxia reversed by naloxone
    Barkin, RL
    PHARMACOTHERAPY, 1996, 16 (05): : 969 - 969
  • [29] Inhibition by lithium of opioid withdrawal-like syndrome and physical dependency in a model of acute cholestasis in mice
    Dehpour, AR
    Meysami, F
    Ebrahimi-Daryani, N
    Akbarloo, N
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1998, 13 (06) : 407 - 412
  • [30] Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine
    Popik, P
    Danysz, W
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1997, 280 (02): : 854 - 865
12345